At Glenmark, we believe that Research and Development is at the core of everything we do. It is our pursuit to enrich lives globally by meeting the unmet medical needs of the world. Our continuous efforts have resulted into a pipeline of novel molecules focused on chronic indications namely – Inflammation, Pain and Oncology. Presently we have 7 molecules – 2 NCEs and 5 NBEs molecules in various stages of pre-clinical and clinical development. Glenmark has made its mark in the area of novel drug discovery by out-licensing its own molecules in various stages of clinical development to large global multinationals. Glenmark has successfully out-licensed seven molecules to five companies and have received a total of USD 217 million in up-front and milestone payments, cumulatively. We are the only company from emerging markets to execute multiple deals on novel molecules.
Our endeavour is catalysed by our strong research infrastructure and our team of experts. Our R&D centre in Navi Mumbai, India is focused on the discovery of new chemical entities and the Switzerland R&D Centre is focused on discovery and development of new biological entities. Glenmark has developed its own proprietary platform for bispecific antibodies - BEAT® at its Switzerland R&D Centre. Our global R&D capabilities is also reflected by the fact that we have approved clinical trial sites in over 20 countries.
Our team of highly qualified scientists and our extensive R&D capabilities across the globe, move us closer to our vision.